Beijing Vigoo Biological Says EV71 Vaccine Passes Phase III Test
Published: May 30, 2013
by Richard Daverman, PhD
May 29, 2013 -- Beijing Vigoo Biological, a vaccine-focused subsidiary of China National Biotec Group, reported that its Enterovirus 71 vaccine was effective in up to 90% of test subjects. The company carried out a large Phase III trial in 10,245 children, aged 6 to 35 months. Half were randomized to receive vaccine. EV71, which strikes mainly children under the age of five, is a major cause of hand, foot and mouth disease. More details....
Help employers find you! Check out all the jobs and post your resume.